NL-OMON40482已完成不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF SINGLE INTRAVENOUS DOSES OF GNX-5086 IN HEALTHY SUBJECTS - GNX-5086 SAD study
Congenia S.r.l.0 个研究点目标入组 105 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male
- •25 - 45 years inclusive
- •BMI 18.0 - 30.0 kg/m2 inclusive
- •non-smoker
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS.
- •Participation in another drug study within 60 days prior to randomization.
- •Any donation of blood(products) or significant blood loss within 60 days prior to drug administration
研究者
相似试验
已完成
2 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUStype 2 diabetes mellitus10012653diabetesNL-OMON34301Hanmi Pharmaceutical Company Ltd48
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS - HM11260C SAD study in patients with type 2 diabetes mellitustype 2 diabetes mellitusMedDRA version: 12.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2010-019665-28-NLHanmi Pharmaceutical Company Limited
已完成
4 期
A clinical study to assess the benefits of Concentrace Trace Mineral Drops-(CTMD®), a food supplement in subjects with OSTEOARTHRITIS (OA) of knee jointCTRI/2010/091/001105Dr. Himanshu Bansal100
进行中（未招募）
1 期
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-GBF. Hoffmann-La Roche Ltd.129
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-ESF. Hoffmann-La Roche Ltd.180